trinity biotech - TRIB

TRIB

Close Chg Chg %
9.41 -0.35 -3.72%

Pre-Market

9.06

-0.35 (3.72%)

Volume: 10.06K

Last Updated:

Sep 8, 2026, 4:00 PM EDT

Company Overview: trinity biotech - TRIB

TRIB Key Data

Open

$9.31

Day Range

8.80 - 9.67

52 Week Range

7.94 - 52.50

Market Cap

$6.07M

Shares Outstanding

644.60K

Public Float

621.60K

Beta

0.97

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$52.93

Yield

0.00%

Dividend

$0.22

EX-DIVIDEND DATE

Jun 5, 2015

SHORT INTEREST

N/A

AVERAGE VOLUME

30.93K

 

TRIB Performance

1 Week
 
-3.72%
 
1 Month
 
-27.11%
 
3 Months
 
-53.54%
 
1 Year
 
-74.62%
 
5 Years
 
-97.74%
 

TRIB Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About trinity biotech - TRIB

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World-Ireland geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

TRIB At a Glance

Trinity Biotech Plc
IDA Business Park
Bray, Wicklow 10
Phone 353-1-276-9800 Revenue 43.92M
Industry Medical Specialties Net Income -37,491,648.94
Sector Health Technology Employees 287
Fiscal Year-end 12 / 2026
View SEC Filings

TRIB Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.335
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -17.854
Enterprise Value to Sales 3.359
Total Debt to Enterprise Value 0.935

TRIB Efficiency

Revenue/Employee 153,033.03
Income Per Employee -130,632.923
Receivables Turnover 4.272
Total Asset Turnover 0.421

TRIB Liquidity

Current Ratio 0.254
Quick Ratio 0.121
Cash Ratio 0.036

TRIB Profitability

Gross Margin 35.405
Operating Margin -24.945
Pretax Margin -84.908
Net Margin -85.363
Return on Assets -35.971
Return on Equity N/A
Return on Total Capital -56.805
Return on Invested Capital -410.283

TRIB Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 209.062
Total Debt to Total Assets 131.206
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 41.166
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Trinity Biotech - TRIB

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
74.82M 56.92M 61.45M 43.92M
Sales Growth
-19.39% -23.92% +7.95% -28.52%
Cost of Goods Sold (COGS) incl D&A
53.68M 38.39M 41.23M 28.37M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.33M 1.78M 1.86M 2.69M
Depreciation
1.41M 831.29K 673.81K 1.30M
Amortization of Intangibles
923.51K 947.47K 1.19M 1.39M
COGS Growth
-3.65% -28.49% +7.41% -31.19%
Gross Income
21.14M 18.53M 20.22M 15.55M
Gross Income Growth
-43.03% -12.32% +9.08% -23.08%
Gross Profit Margin
+28.25% +32.56% +32.90% +35.40%
2022 2023 2024 2025 5-year trend
SG&A Expense
33.33M 33.82M 31.74M 26.51M
Research & Development
4.14M 4.39M 4.53M 3.64M
Other SG&A
29.19M 29.43M 27.20M 22.87M
SGA Growth
+15.99% +1.45% -6.15% -16.48%
Other Operating Expense
- - - 482.26K
-
Unusual Expense
5.63M 11.61M 9.27M 4.39M
EBIT after Unusual Expense
(18.31M) (26.89M) (20.79M) (15.34M)
Non Operating Income/Expense
1.85M 977.51K (335.41K) (495.53K)
Non-Operating Interest Income
- - 303.17K 1.17M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
24.76M 11.07M 9.55M 21.45M
Interest Expense Growth
+249.41% -55.29% -13.75% +124.70%
Gross Interest Expense
24.76M 11.07M 9.55M 21.45M
Interest Capitalized
- - - -
-
Pretax Income
(41.22M) (36.98M) (30.68M) (37.29M)
Pretax Income Growth
-5,596.83% +10.27% +17.06% -21.57%
Pretax Margin
-55.09% -64.98% -49.92% -84.91%
Income Tax
(192.11K) (59.09K) 485.14K 199.62K
Income Tax - Current - Domestic
(270.15K) (198.31K) 9.98K 330.02K
Income Tax - Current - Foreign
(5.00K) 462.72K 274.51K 136.42K
Income Tax - Deferred - Domestic
83.05K (323.50K) 200.64K (266.82K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(41.02M) (36.93M) (31.16M) (37.49M)
Minority Interest Expense
- - - -
-
Net Income
(41.02M) (36.93M) (31.16M) (37.49M)
Net Income Growth
-4,522.91% +9.99% +15.61% -20.32%
Net Margin Growth
-54.83% -64.87% -50.71% -85.36%
Extraordinaries & Discontinued Operations
- (7.00K) 12.87M (571.99K)
Discontinued Operations
- (7.00K) 12.87M (571.99K)
Net Income After Extraordinaries
(41.03M) (24.06M) (31.73M) (37.49M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(41.03M) (24.06M) (31.73M) (37.49M)
EPS (Basic)
-182.4459 -94.2738 -53.0062 -60.5468
EPS (Basic) Growth
-3,008.80% +48.33% +43.77% -14.23%
Basic Shares Outstanding
224.90K 255.17K 598.66K 619.19K
EPS (Diluted)
-182.4459 -94.2738 -53.0062 -60.5468
EPS (Diluted) Growth
-3,809.53% +48.33% +43.77% -14.23%
Diluted Shares Outstanding
224.90K 255.17K 598.66K 619.19K
EBITDA
(10.34M) (13.50M) (9.66M) (8.26M)
EBITDA Growth
-198.32% -30.55% +28.48% +14.45%
EBITDA Margin
-13.83% -23.73% -15.72% -18.81%

Trinity Biotech in the News